Newsbenzinga
These Analysts Slash Their Forecasts On Abivax Following H1 Results
· Published
Article summary
Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.
An excerpt from the original article.
Comments —
Loading comments…